· In combination with other small molecules (“CRISPY” mix), MLN4924 has been reported to increase precise CRISPR-Cas9 genome editing in human pluripotent stem cells (Riesenberg & Maricic).
· By blocking NAE and proteasome, MLN4924 together with bortezomib inhibits AKT and mTOR and induces apoptosis in multiple myeloma cell lines (Gu et al.).
This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.